Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax ® platform in the treatment of glioblastoma multiforme
- 13 March 2015
- journal article
- research article
- Published by Taylor & Francis in CNS Oncology
- Vol. 4 (2) , 63-69
Abstract
SUMMARY DCVax® (Northwest Biotherapeutics, Inc., MD, USA) is a platform technology for delivering dendritic cell based therapeutic vaccines for a variety of cancers, including glioblastoma multifo...Keywords
This publication has 26 references indexed in Scilit:
- Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancerOncoImmunology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to BedsideJournal of Clinical Oncology, 2012
- An extent of resection threshold for newly diagnosed glioblastomasJournal of Neurosurgery, 2011
- DCVax®-Brain and DC vaccines in the treatment of GBMExpert Opinion on Investigational Drugs, 2009
- Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse EventsThe Oncologist, 2007
- Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trialActa Neurochirurgica, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJournal of Neurosurgery, 2001
- Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissueJournal of Neurosurgery, 1981